Dose-escalating, phase II study to assess the safety and tolerability of RG2417 [uridine] in the treatment of bipolar I depression
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2008
At a glance
- Drugs Uridine (Primary)
- Indications Bipolar disorders; Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Repligen Corporation
- 06 Nov 2008 Efficacy and tolerability results reported in a Repligen media release.
- 12 Jun 2008 Final results have been reported in a Repligen media release.
- 08 Nov 2007 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History